Premium
Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus
Author(s) -
Vesell Elliot S.,
Chambers Charles E.,
Passananti G. Thomas,
Demers Laurence M.,
Beyer Karl H.
Publication year - 1993
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1993.tb01958.x
Subject(s) - hyperinsulinemia , medicine , diabetes mellitus , hydrochlorothiazide , endocrinology , hyperlipidemia , insulin , diastole , blood pressure , insulin resistance
Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients.